(Ovarian Cancer) Is Lynparza + Cediranib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On March 15, 2022, Joyce F. Liu et al. from Dana-Farber Cancer Institute published results from the NRG-GY004 Phase III clinical trial in the Journal of Clinical Oncology, evaluating the efficacy and safety of PARP inhibitor Lynparza (olaparib) plus oral VEGF inhibitor Cediranib in platinum-sensitive recurrent ovarian cancer patients.
NRG-GY004 was an open-label, randomized Phase III clinical trial that assigned platinum-sensitive recurrent ovarian cancer patients (N=565) in a 1:1:1 ratio to either the platinum chemotherapy group, Lynparza monotherapy group, or Lynparza + Cediranib group. The primary endpoint was progression-free survival (PFS) for all patients.
The trial results showed that the median PFS (primary endpoint) for all patients was 10.3 months for the platinum chemotherapy group, 8.2 months for the Lynparza monotherapy group, and 10.4 months for the Lynparza + Cediranib group. The Lynparza + Cediranib group showed a 14% reduction in the risk of disease progression or death compared to the platinum chemotherapy group, without a significant difference.
In germline BRCA mutation-positive patients, the Lynparza + Cediranib group showed a 45% reduction in risk versus platinum chemotherapy, and the Lynparza monotherapy group showed a 37% reduction. In germline BRCA mutation-negative patients, the Lynparza + Cediranib group showed a 3% reduction versus platinum chemotherapy, while the Lynparza monotherapy group showed a 41% increase in risk.
Regarding safety, the platinum chemotherapy group most commonly experienced hematological adverse events, while the Lynparza + Cediranib group most commonly experienced non-hematological adverse events.
Based on the NRG-GY004 trial results, Joyce F. Liu et al. stated: "In platinum-sensitive recurrent ovarian cancer patients, PARP inhibitor Lynparza plus oral VEGF inhibitor Cediranib did not show a significant improvement in progression-free survival compared to platinum chemotherapy, but PFS was improved in germline BRCA mutation-positive patients."
Source: https://ascopubs.org/doi/abs/10.1200/JCO.21.02011
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4